Microbiology Department, Virology Division, College of Medicine, Taif University, Al-Taif, Saudi Arabia.
Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.
Virology. 2021 Jun;558:1-12. doi: 10.1016/j.virol.2021.02.007. Epub 2021 Feb 22.
SARS-CoV-2 is a novel coronavirus, spread among humans, and to date, more than 100 million of laboratory-confirmed cases have been reported worldwide. The virus demonstrates 96% similarity to a coronavirus from a horseshoe bat and most probably emerged from a spill over from bats or wild animal(s) to humans. Currently, two variants are circulating in the UK and South Africa and spread to many countries around the world. The impact of mutations on virus replication, virulence and transmissibility should be monitored carefully. Current data suggest recurrent infection with SARS-CoV-2 correlated to the level of neutralising antibodies and with sustained memory responses following infection. Recently, remdesivir was FDA approved for treatment of COVID-19, however many potential antivirals are currently in different clinical trials. Clinical data and experimental studies indicated that licenced vaccines are helpful in controlling the disease. However, the current vaccines should be evaluated against the emerging variants of SARS-CoV-2.
新型冠状病毒（SARS-CoV-2）是一种在人类中传播的新型冠状病毒，迄今为止，全球已报告超过 1 亿例实验室确诊病例。该病毒与来自马蹄蝠的冠状病毒相似度达 96%，极有可能是由蝙蝠或野生动物溢出到人类身上而出现的。目前，两种变异株正在英国和南非流行，并传播到世界各地许多国家。应密切监测突变对病毒复制、毒力和传染性的影响。目前的数据表明，SARS-CoV-2 的反复感染与中和抗体水平以及感染后的持续记忆反应有关。最近，瑞德西韦获得了美国食品药品监督管理局（FDA）批准用于治疗 COVID-19，然而，目前有许多潜在的抗病毒药物正在进行不同的临床试验。临床数据和实验研究表明，已许可的疫苗有助于控制疾病。然而，目前的疫苗应该针对 SARS-CoV-2 的新出现变异株进行评估。
